Press Release: Novartis announces new data that -2-

regulation generally; global trends toward health care cost containment,

including government, payor and general public pricing and reimbursement

pressures; our ability to obtain or maintain proprietary intellectual

property protection; the particular prescribing preferences of

physicians and patients; general political and economic conditions;

safety, quality or manufacturing issues; potential or actual data

security and data privacy breaches, or disruptions of our information

technology systems, and other risks and factors referred to in Novartis

AG's current Form 20-F on file with the US Securities and Exchange

Commission. Novartis is providing the information in this press release

as of this date and does not undertake any obligation to update any

forward-looking statements contained in this press release as a result

of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the

evolving needs of patients and societies. Headquartered in Basel,

Switzerland, Novartis offers a diversified portfolio to best meet these

needs: innovative medicines, cost-saving generic and biosimilar

pharmaceuticals and eye care. Novartis has leading positions globally in

each of these areas. In 2017, the Group achieved net sales of USD 49.1

billion, while R&D throughout the Group amounted to approximately USD

9.0 billion. Novartis Group companies employ approximately 125,000

full-time-equivalent associates. Novartis products are sold in

approximately 155 countries around the world. For more information,

please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartis

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

[1] Wachter R. et al., Initiation of sacubitril/valsartan in

hospitalized patients with heart failure with reduced ejection fraction

after hemodynamic stabilization: Primary results of the TRANSITION

study. Data presented at: ESC 2018, Aug 25-29; Munich, Germany.

[2] Yancy CW. et al., 2013 ACCF/AHA Guideline for the Management of

Heart Failure, J Am Coll Cardiol. 2013; 62(16):e147-e239.

[3] Dharmarajan K, Hsieh AF, Lin Z, et al., Diagnoses and Timing of

30-Day Readmissions after Hospitalization For Heart Failure, Acute

Myocardial Infarction, or Pneumonia. JAMA. 2013;309(4):355-363.

[4] Bueno H, Ross JS, Wang Y, et al., Trends in Length of Stay and

Short-Term Outcomes among Medicare Patients Hospitalized for Heart

Failure: 1993-2008. JAMA. 2010;303(21):2141-2147.

[5] McMurray JJV., et al., Angiotensin-Neprilysin Inhibition versus

Enalapril in Heart Failure. N Engl J Med 2014; 371:993-1004.

[6] Desai, AS., et al., Influence of Sacubitril/Valsartan (LCZ696) on

30-Day Readmission After Heart Failure Hospitalization. JACC

2016;68(3):241-248.

[7] Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and

outcome of heart failure with preserved ejection fraction. N Engl J Med.

2006;355:251-259.

[8] Maggioni, AP., et al., Are hospitalized or ambulatory patients

with heart failure treated in accordance with European Society of

Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart

Failure Long-Term Registry. Eur J Heart Fail. 2013 Oct;15(10):1173-84.

[9] Pascual-Figal D., et al., Rationale and design of TRANSITION: a

randomized trial of pre-discharge vs. post-discharge initiation of

sacubitril/valsartan. ESC Heart Fail. 2018 Apr;5(2):327-336.

[10] EMA. Entresto (sacubitril/valsartan). Summary of product

characteristics. Available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004062/WC500197536.pdf

[Last accessed: July 2018]

[11] Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition

with LCZ696: a novel approach for the treatment of heart failure. Drug

Discov Today. 2012:4: e131-139.

[12] FDA. Entresto (sacubitril/valsartan). Highlights of prescribing

information. Available at:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf

[Last accessed: July 2018]

[13] Chandra, A. et al., The Effects of Sacubitril/Valsartan on Physical

and Social Activity Limitations in Heart Failure Patients: The

PARADIGM-HF Trial. JAMA Cardiol. 2018;3(6):498-505.

[14] Azad N, Lemay G. Management of chronic heart failure in the older

population. Journal of Geriatric Cardiology: JGC. 2014;11(4):329-337.

[15] Savarese G and Lund LH. Global Public Health Burden of Heart

Failure Card Fail Rev. 2017 Apr; 3(1): 7-11.

[16] Ambrosy A, Fonarow G, Butler J. et al., The global health and

economic burden of hospitalizations for heart failure. J Am Coll Cardio.

2014, 63 (12), 1123-33.

[17] Ponikowski P. et al., 2014. Heart failure. Preventing disease and

death worldwide. Available at:

https://www.escardio.org/static_file/Escardio/Subspecialty/HFA/WHFA-whitepaper-15-May-14.pdf

[Last accessed: July 2018]

[18] Cook C, Cole G, Asaria P. et al., The annual global economic burden

of heart failure. Int J Cardiol. 2014.;171(3):368-76.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff Agnes Estes

Novartis Global Media Relations Novartis Cardio-Metabolic Communications

+41 61 324 7999 (direct) +41 61 324 1986 (direct)

+41 79 593 4202 (mobile) +41 79 644 1062 (mobile)

eric.althoff@novartis.com agnes.estes@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2212679/862778.pdf

This announcement is distributed by Nasdaq Corporate Solutions on behalf

of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

August 25, 2018 05:00 ET (09:00 GMT)